Literature DB >> 11168800

Ganglioside modulates ligand binding to the epidermal growth factor receptor.

X Wang1, Z Rahman, P Sun, E Meuillet, D George, E G Bremer, A Al-Qamari, A S Paller.   

Abstract

Whereas previous investigations have shown that pharmacologic addition of gangliosides inhibits keratinocyte proliferation by downregulating epidermal growth factor receptor phosphorylation, the underlying biochemical basis and physiologic relevance are unknown. Using Scatchard and displacement plots, we have shown that supplemental purified gangliosides decrease the binding of (125)I-labeled epidermal growth factor to keratinocyte-derived SCC12 cells. Conversely, SCC12 cells transfected with sialidase and thus depleted of gangliosides show increased ligand binding to the epidermal growth factor receptor, which is consistent with their increased proliferation in response to epidermal growth factor and transforming growth factor-alpha, and increased phosphorylation of the epidermal growth factor receptor, and downstream signal transduction pathway components. The mechanism of the altered binding appears to involve primarily decreased numbers of available receptors within the intact membrane, but not altered receptor protein expression. These studies provide evidence that the effect of gangliosides on keratinocyte proliferation results, at least in part, from the direct binding of ganglioside to the receptor and disruption of the receptor-ligand interaction. Manipulation of membrane ganglioside content may be a powerful new means to alter epidermal growth factor receptor-dependent cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168800     DOI: 10.1046/j.1523-1747.2001.00222.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  The tethering arm of the EGF receptor is required for negative cooperativity and signal transduction.

Authors:  Sangeeta Adak; Diana DeAndrade; Linda J Pike
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

2.  Ganglioside GM3 Mediates Glucose-Induced Suppression of IGF-1 Receptor-Rac1 Activation to Inhibit Keratinocyte Motility.

Authors:  Duncan Hieu M Dam; Xiao-Qi Wang; Sarah Sheu; Mahima Vijay; Desmond Shipp; Luke Miller; Amy S Paller
Journal:  J Invest Dermatol       Date:  2016-10-08       Impact factor: 8.551

Review 3.  Glycosphingolipids and cell death.

Authors:  Meryem Bektas; Sarah Spiegel
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 4.  Gangliosides in Diabetic Wound Healing.

Authors:  Duncan Hieu M Dam; Amy S Paller
Journal:  Prog Mol Biol Transl Sci       Date:  2018-03-17       Impact factor: 3.622

Review 5.  Protein Toxins That Utilize Gangliosides as Host Receptors.

Authors:  Madison Zuverink; Joseph T Barbieri
Journal:  Prog Mol Biol Transl Sci       Date:  2018-03-17       Impact factor: 3.622

6.  Gangliosides play an important role in the organization of CD82-enriched microdomains.

Authors:  Elena Odintsova; Terry D Butters; Eugenio Monti; Hein Sprong; Gerrit van Meer; Fedor Berditchevski
Journal:  Biochem J       Date:  2006-12-01       Impact factor: 3.857

Review 7.  Targeting the Sphingolipid Rheostat in Gliomas.

Authors:  Faris Zaibaq; Tyrone Dowdy; Mioara Larion
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

8.  Ganglioside GM3 depletion reverses impaired wound healing in diabetic mice by activating IGF-1 and insulin receptors.

Authors:  Xiao-Qi Wang; Sarah Lee; Heather Wilson; Mark Seeger; Hristo Iordanov; Nandita Gatla; Adam Whittington; Daniel Bach; Jian-Yun Lu; Amy S Paller
Journal:  J Invest Dermatol       Date:  2013-12-10       Impact factor: 8.551

9.  Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.

Authors:  Addys González Palomo; Rancés Blanco Santana; Xiomara Escobar Pérez; Damián Blanco Santana; Mariano Rolando Gabri; Kalet León Monzon; Adriana Carr Pérez
Journal:  Clin Exp Metastasis       Date:  2016-07-23       Impact factor: 5.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.